Mazdutide

With completion of the project expected to occur by the end of 2026, Novo will use the new facility to handle quality control at its Tianjin plant. A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back for another expansion project at its flagship factory in Tianjin.Novo Nordisk on Tuesday inked a deal with the Tianjin Economic and Technological Development Area (TEDA) to invest 800 million Chinese yuan (roughly $112 million) in an upgrade to the quality testing laboratory at its Tianjin manufacturing facility, which has been in operation since 1994.The new testing facility is expected to cover some 18,000 square meters (around 194,000 square feet), housing chemical, biological and microbiological labs, according to a Chinese-language press release from TEDA.With completion of the project expected to occur by the end of 2026, Novo will use the new facility to handle quality control testing at its Tianjin plant. The site is one of the Danish drugmaker’s seven core manufacturing hubs worldwide.TEDA didn’t disclose the specific drugs Novo’s new testing lab will vet, though other recent projects at the company’s Tianjin site have focused on pre-filled injection pen production and sterile drug manufacturing for products like Ozempic and Wegovy. Last March, as Novo celebrated three decades of business in China, the company deployed 4 billion yuan (then $556 million) in Tianjin as part of a sterile preparation expansion project. The expansion was expected to wrap up in 2027, Novo said at the time.In announcing last year’s Tianjin investment, Novo noted that the project was expected to boost production capacity in China to “meet the needs of Chinese patients for innovative drugs.”With the latest project, Novo’s total investment in Tianjin is slated to surpass 10 billion yuan (around $1.4 billion), TEDA noted in its release. Novo employed nearly 7,000 people across mainland China, Hong Kong and Taiwan in 2024, according to its latest annual report (PDF), and more than 1,700 people at its Tianjin production plant specifically.China, like many other countries, has been swept up in the weight loss boom spurred by the approvals of highly effective GLP-1 obesity medicines from Novo Nordisk and Eli Lilly. At the same time, many other local drugmakers are working to advance their own obesity prospects through the clinic.Novo’s Ozempic for type 2 diabetes has been approved in China since 2021, while the company’s sister drug for obesity, Wegovy, scored a green light in the country last June. Novo kicked off its Wegovy launch in China around mid-November, Reuters reported last year. In 2024, Ozempic sales in China reached 5.76 billion Danish kroner ($904 million), while the company's total GLP-1 sales in the country climbed to 7.2 billion kroner (roughly $1.14 billion). As in other parts of the world, Novo is competing with Eli Lilly for control of the Chinese GLP-1 market, though local biopharma outfits are making headway as well.Late last month, Innovent Biologics scored a thumbs up from China’s drug regulator for the world’s first dual GLP-1/glucagon (GCP) receptor agonist, mazdutide, for chronic weight management in Chinese adults who are overweight or have obesity. Innovent secured Chinese rights to mazdutide from Lilly in 2019, with Lilly still in control of the asset in other global territories.

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1) were orally presented (Abstract #: 306-OR) at the 85th Scientific Sessions of the American Diabetes Association (ADA), with Dr. Lei Qian from Innovent Biologics, as the presenter. The DREAMS-1 clinical study met its primary endpoint and all key secondary endpoints in July 2024. Mazdutide demonstrated dual benefits in glycemic control and weight loss, along with comprehensive improvements in cardiovascular, renal, and metabolic indicators. These findings provide important evidence-based medical support for the use of next-generation GCG/GLP-1 receptor agonists in treating T2D. In August 2024, mazdutide's NDA for glycemic control of T2D patients was accepted by China's National Medical Products Administration (NMPA) for review. It is expected to offer a better treatment option for Chinese T2D patients soon. Continue Reading Oral Presentation at 2025 ADA DREAMS-1 (ClinicalTrials.gov, NCT05628311) enrolled 319 Chinese participants with T2D inadequately controlled by diet and exercise alone (mean age 50.4 years, mean baseline HbA1c 8.24%, mean baseline body weight 77.7 kg). Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or placebo for 24 weeks. The primary endpoint was the change in HbA1c from baseline to week 24. Mazdutide demonstrated robust glucose-lowering efficacy, achieving HbA1c reduction of 2.15% after 24 weeks of treatment For the efficacy estimand, the change in HbA1c from baseline to week 24 were -1.57% and -2.15% for mazdutide 4 mg and mazdutide 6 mg, respectively, demonstrating superiority to placebo (-0.14%). At week 24, 68.6% and 87.4% of participants receiving mazdutide 4 mg and 6 mg, respectively, achieved HbA1c <7.0% compared to 10.7% with placebo. Additionally, 55.6% and 81.5% of participants receiving mazdutide 4 mg and 6 mg, respectively, achieved HbA1c ≤6.5%, compared to 4.4% with placebo. Mazdutide demonstrated robust efficacy in both glycemic control and weight reduction For the efficacy estimand, after 24 weeks of treatment, the percentage change in body weight from baseline to week 24 were -5.61% and -7.81% for mazdutide 4 mg and mazdutide 6 mg, respectively, demonstrating superiority to placebo (-1.26%). At week 24, 50.9% and 69.0% of participants receiving mazdutide 4 mg and mazdutide 6 mg achieved a weight reduction of ≥5%, compared to 7.3% with placebo. Additionally, 40.6% and 64.9% of participants treated with mazdutide 4 mg and mazdutide 6 mg achieved both a weight reduction of ≥5% and HbA1c < 7.0%, respectively (vs. placebo: 0%). Improvements in multiple cardiometabolic risk factors Mazdutide treatment also led to significant and clinically meaningful improvements on fasting glucose, self-measured blood glucose, waist circumference, blood pressure, lipids, and transaminases. Favorable safety profile and no new safety signals observed Mazdutide was well tolerated, with low incidence of TEAEs leading to treatment discontinuation. Gastrointestinal symptoms were the most common adverse events, mostly mild to moderate severity, transient, and occurring mainly during dose escalation. Low incidence of hypoglycemia, and no severe hypoglycemia was reported. The overall safety profile was consistent with previous clinical studies of mazdutide, with no new safety signals observed. Mazdutide is the most advanced dual GCG/ GLP-1 receptor agonist in clinical development, with two NDAs currently under review by China's NMPA: (1) Chronic weight management in adults with obesity or overweight (2) Glycemic control in adults with type 2 diabetes Professor Lixin Guo, the Principal Investigator of DREAMS-1, Nanjing University Affiliated Drum Tower Hospital, said: "China has a high incidence of T2D, with 140 million adult patients, ranking first in the world. A significant proportion of these patients also suffer from overweight/obesity, cardiovascular diseases, and/or kidney diseases, making prevention and treatment a formidable challenge. There is an urgent need for more effective and safer innovative drugs. In recent years, GLP-1 receptor agonists have emerged as a superior treatment option for type 2 diabetes due to their comprehensive benefits in blood glucose control, weight management, and cardiovascular and renal health. Mazdutide, as a dual GCG/GLP-1 receptor agonist, demonstrated superior efficacy compared to placebo in glycemic control and weight reduction in the DREAMS-1 study in Chinese patients with T2D inadequately controlled by diet and exercise alone. It also showed a favorable safety profile. Additionally, mazdutide offers comprehensive benefits such as reduced waist circumference, blood pressure, and lipid levels. I am delighted to see the study results presented as an oral presentation at ADA congress and look forward to mazdutide's approval in near future, providing a new treatment option for T2D patients in China and improving their clinical outcomes." Professor Jiajun Zhao, the Principal Investigator of DREAMS-1, Shandong Provincial Hospital, said: "In recent years, the treatment for diabetes has gradually shifted from mere blood glucose control to a 'patient-centered' approach, integrating glycemic control, weight management, cardiovascular risk factor management, and addressing cardiorenal comorbidities and complications. GLP-1 receptor agonists not only excel in glycemic control but also effectively reduce weight, making them a hotspot and frontier in metabolic disease drug development. The pivotal clinical study DREAMS-1 for mazdutide, a dual GCG/GLP-1 receptor agonist, was orally presented at ADA 85th Scientific Sessions, reaffirming its outstanding efficacy in glucose-lowering and weight reduction, multiple metabolic benefits, and favorable safety profile. We hope it will soon benefit Chinese patients with T2D." Dr. Lei Qian from Innovent Biologics said: "I am pleased to orally present the results of DREAMS-1 at this year's ADA conference, which demonstrated its comprehensive benefits in glycemic control, weight reduction, and multiple metabolic indicators. This also reflects the outstanding research capabilities of Chinese investigators and Innovent's solid clinical development strength. The detailed results of DREAMS-1 and another Phase 3 study (DREAMS-2), which compared mazdutide with dulaglutide combined with oral hypoglycemic drugs in Chinese T2D patients, will also be published in academic journals. We hope mazdutide will soon be approved and launched, benefiting the vast number of T2D patients in need of comprehensive improvements in blood glucose, weight, and cardiovascular metabolic indicators. Innovent will continue to develop a next-generation pipeline in the cardiovascular and metabolic fields, meeting the public's aspirations for a healthier life and serving more patients." About Diabetes According to the 2021 global diabetes overview by the International Diabetes Federation, China leads the world in the number of patients with diabetes, with an estimated 140 million cases in 2021 and projected to reach 174 million by 2045[1]. Poor glycemic control can lead to irreversible microvascular and macrovascular complications, including reduced visual acuity, blindness, renal dysfunction, peripheral neuropathy, myocardial infarction, stroke and amputation[2]. The high prevalence of diabetes and its serious complications pose a significant threat to human health. Currently, various therapeutic approaches are available for diabetes management. In addition to controlling blood glucose, new hypoglycemic drugs are being developed to offer additional benefits such as weight loss, cardiovascular risk reduction and kidney protection[3]. About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Mazdutide currently has two NDAs accepted for review by NMPA, including: For chronic weight management in adults with overweight of obesity; For glycemia control in adults with type 2 diabetes. Mazdutide is currently being evaluated in seven Phase 3 clinical studies, including: GLORY-1: A Phase 3 study in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 study in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 study comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). GLORY-OSA: A Phase 3 study in Chinese participants with obstructive sleep apnea (OSA) and obesity; DREAMS-1: A Phase 3 study in treatment-naïve Chinese patients with T2D. DREAMS-2: A Phase 3 study comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 study comparing mazdutide and semaglutide in Chinese patients with T2D and obesity. Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other four studies are currently ongoing. In addition, several new clinical studies of mazdutide are initiated or planned, including: A Phase 3 trial in adolescents with obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED